Association of macrophage migration inhibitory factor gene -173 G/C polymorphism with prognosis in Turkish children with juvenile rheumatoid arthritis.
The objectives of this study were to determine genotypic and allelic frequencies of macrophage migration inhibitory factor (MIF) gene -173 G/C polymorphism in patients with juvenile rheumatoid arthritis (JRA) and to evaluate the association of the MIF -173 C allele with the outcome of JRA. Genomic DNA was collected from 67 JRA patients and 153 healthy individuals. To evaluate the association of the MIF -173 polymorphism with the outcome, we analyzed the data concerning the treatment regimen, duration of glucocorticoid treatment, score on the childhood health assessment questionnaire (C-HAQ) and the number of joints with active arthritis. Nonsignificant differences were observed between the study and control groups in the distribution of genotype and allele frequencies of the MIF gene -173 G/C polymorphism. In JRA patients, carrying a MIF -173 C allele, the number of disease modifying antirheumatic drugs required for the treatment was more, the duration of glucocorticoid treatment was significantly longer, and at the last visits the C-HAQ scores and the number of joints with active arthritis were significantly higher. MIF gene -173 C allele frequency did not differ between the controls and JRA patients. MIF -173 C allele did not confer increased susceptibility to JRA in our study group. Carriage of the MIF -173 C allele was found to be a strong predictor of poor outcome in all types of JRA.
Berdeli
Afig
A
Department of Pediatrics, Laboratory of Molecular Medicine, Ege University School of Medicine, Bornova, 35100, SSK Tepecik Hospital, Izmir, Turkey. afig@med.ege.edu.tr
Ozyürek
Arif Ruhi
AR
Ulger
Zülal
Z
Gürses
Dolunay
D
Levent
Ertürk
E
Salar
Koray
K
Gürpinar
Ali Rahmi
AR
D000483:Alleles; D001171:Arthritis, Juvenile / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D005787:Gene Frequency; D005938:Glucocorticoids / Q000627:therapeutic use; D006579:Heterozygote; D006801:Humans; D008263:Macrophage Migration-Inhibitory Factors / Q000235:genetics*; D008297:Male; D011110:Polymorphism, Genetic; D011379:Prognosis; D013997:Time Factors; D016896:Treatment Outcome; D014421:Turkey / Q000453:epidemiology
D005938:Glucocorticoids; D008263:Macrophage Migration-Inhibitory Factors